OpenAI, Anthropic Back Mandatory AI Breach Reporting in Australia 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
US Pressures Allies to Distance From Anti-Disinformation Conference 
San Francisco Halts New Data Center Construction With 45-Day Moratorium 
Saudi Arabia Probes Flydubai Cockpit Attack 
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
Trump Weighs FBI Probe Into Nolan Wells’ Death 
US Grants Aurora Five-Year Exemption for Self-Driving Trucks 
Lula Weighs Alckmin as Finance Minister to Boost Fiscal Credibility 
France to Release 10 Million Barrels of Diesel to Ease Fuel Prices 
Lincoln University Students Sue Missouri Over Decades of Underfunding 
Mexico Bars Dual Citizens From Presidential Races Starting in 2028 
3 clinical-grade skincare creams you really shouldn’t buy online 
Trump Says He Deserves 2026 Nobel Peace Prize Despite Uncertain Chances 
New York Declares Measles Disaster Emergency as Cases Surge 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Add as a preferred source on Google
U.S. Health Secretary Robert F. Kennedy Jr. told lawmakers this week that he is open to sharing details about David Geier’s contract with the Department of Health and Human Services (HHS), signaling growing scrutiny over the controversial appointment. During a Senate Finance Committee hearing, Kennedy stated that the contract could be provided to senators before the end of the week, offering what may become the first clear explanation of Geier’s responsibilities within the agency.
David Geier, known for his long-standing anti-vaccine activism, is currently working as a contractor tied to the Centers for Disease Control and Prevention (CDC). According to federal records, he is listed as a senior data analyst within the HHS system. His involvement has raised concerns among lawmakers and public health experts, particularly given his history of promoting debunked claims linking vaccines to autism.
Senator Ben Ray Luján of New Mexico pressed Kennedy on whether the administration would also release the protocols guiding Geier’s work. Kennedy responded that such protocols are not yet in place but promised they would be shared once the vaccine safety review is completed. Kennedy has previously indicated that Geier is leading a review of CDC vaccine data, a move that has sparked debate due to Geier’s controversial background.
Geier’s past actions have added to the concern. He was previously fined in Maryland for practicing medicine without a license and for administering unsafe treatments to children with autism. Critics argue that his involvement in federal health initiatives could undermine public trust in vaccine safety.
The situation highlights ongoing tensions around vaccine policy, public health transparency, and the role of individuals with disputed scientific views in government positions. As pressure builds, the release of Geier’s HHS contract could play a key role in shaping public and political response to the administration’s handling of vaccine-related issues.
